Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
68
PLX Quote, Financials, Valuation and Earnings
Last price:
$1.76
Seasonality move
:
19.62%
Day range:
$1.69 - $1.79
52-week range:
$0.82 - $1.90
Dividend yield:
0%
P/E ratio:
115.00x
P/S ratio:
3.03x
P/B ratio:
4.00x
Volume:
344.3K
Avg. volume:
475.6K
1-year change:
2.92%
Market cap:
$129.6M
Revenue:
$65.5M
EPS (TTM):
-$0.16
Analysts' Opinion
-
Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Protalix BioTherapeutics has an estimated upside of 695.46% from its current price of $1.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.76.
Fair Value
-
According to the consensus of 0 analysts, Protalix BioTherapeutics has 695.46% upside to fair value with a price target of -- per share.
PLX vs. S&P 500
-
Over the past 5 trading days, Protalix BioTherapeutics has underperformed the S&P 500 by -0.24% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Protalix BioTherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protalix BioTherapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Protalix BioTherapeutics reported revenues of $18M.
Earnings Growth
-
Protalix BioTherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Protalix BioTherapeutics reported earnings per share of $0.03.
Enterprise value:
102.2M
EV / Invested capital:
3.15x
Price / LTM sales:
3.03x
EV / EBIT:
5.77x
EV / Revenue:
2.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.25x
Price / Operating cash flow:
19.27x
Enterprise value / EBITDA:
5.12x
Gross Profit (TTM):
$16.4M
Return On Assets:
-11.58%
Net Income Margin (TTM):
-21.04%
Return On Equity:
-29.54%
Return On Invested Capital:
-19.69%
Operating Margin:
22.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $47.6M | $63.6M | $45.7M | $10.3M | $18M | |
| Gross Profit | $27.2M | $47.1M | $16.4M | $5.5M | $9.6M | |
| Operating Income | -$16.2M | $13.6M | -$8.9M | -$1.9M | $4M | |
| EBITDA | -$14M | $16M | -$6.5M | -$954K | $4.5M | |
| Diluted EPS | -$0.37 | $0.05 | -$0.16 | -$0.04 | $0.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $60.3M | $71.2M | $45.8M | $72.6M | $47.9M | |
| Total Assets | $72.3M | $83.5M | $56.7M | $87.6M | $61.6M | |
| Current Liabilities | $43.9M | $42.8M | $34.3M | $43.4M | $24.2M | |
| Total Liabilities | $105.6M | $83.3M | $68.2M | $49.3M | $29.1M | |
| Total Equity | -$33.3M | $213K | -$11.5M | $38.2M | $32.4M | |
| Total Debt | $57.8M | $31.1M | $28.1M | $20.2M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.5M | -$7.5M | $8.3M | -$6.9M | $4.1M | |
| Cash From Investing | $27.4M | -$11.4M | $19.2M | -$20.9M | $20.3M | |
| Cash From Financing | $117K | $28.7M | -$20.4M | -- | -$20.4M | |
| Free Cash Flow | -$28.3M | -$8.6M | $7.2M | -$7.3M | $4M | |
PLX
Sector
Market Cap
$129.6M
$43.9M
Price % of 52-Week High
92.63%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
5.36%
-0.74%
1-Year Price Total Return
2.92%
-29.11%
Beta (5-Year)
0.741
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.76
200-day SMA
Buy
Level
$1.21
Bollinger Bands (100)
Buy
Level
0.93 - 1.51
Chaikin Money Flow
Sell
Level
-285.7M
20-day SMA
Buy
Level
$1.72
Relative Strength Index (RSI14)
Buy
Level
63.36
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-26.9334
50-day SMA
Buy
Level
$1.43
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
176.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.2131)
Sell
CA Score
(Annual)
Level (-0.8879)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.1559)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Stock Forecast FAQ
In the current month, PLX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PLX average analyst price target in the past 3 months is --.
-
Where Will Protalix BioTherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protalix BioTherapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Protalix BioTherapeutics?
Analysts are divided on their view about Protalix BioTherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protalix BioTherapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Protalix BioTherapeutics's Price Target?
The price target for Protalix BioTherapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protalix BioTherapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PLX?
You can purchase shares of Protalix BioTherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protalix BioTherapeutics shares.
-
What Is The Protalix BioTherapeutics Share Price Today?
Protalix BioTherapeutics was last trading at $1.76 per share. This represents the most recent stock quote for Protalix BioTherapeutics. Yesterday, Protalix BioTherapeutics closed at $1.76 per share.
-
How To Buy Protalix BioTherapeutics Stock Online?
In order to purchase Protalix BioTherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
